Hizli Fatih, Uygur M Cemil
Department of Urology, Oncology Education and Research Hospital, Ankara, Turkey.
Int Urol Nephrol. 2007;39(3):879-86. doi: 10.1007/s11255-006-9106-5. Epub 2007 Jan 4.
Increasing attention has been focused on the use of phytotherapeutic agents to alleviate the symptoms of benign prostatic hyperplasia (BPH) in recent times. The best described and studied phytotherapeutic agent is Serenoa repens (SR).
This prospective study was designed to have 3 arms including SR 320 mg per day (N = 20), Tamsulosin (TAM) 0.4 mg per day (N = 20) and SR + TAM (N = 20) to reveal the superiority or equivalence between these treatment regimens in BPH.
The groups were not statistically different with regard to increase in maximal urinary flow rate (Q (max)) and decrease in International Prostate Symptom Score (I-PSS) (P > 0.05). No adverse effect was detected in SR therapy group.
Treatment of BPH by both SR and TAM seems to be effective alone. None of them had superiority to another and additionally, combined therapy (SR + TAM) does not provide extra benefits. Furthermore SR is a well-tolerated agent that can be used alternatively in the treatment of LUTS due to BPH.
近年来,植物治疗剂在缓解良性前列腺增生(BPH)症状方面的应用受到了越来越多的关注。描述和研究得最为充分的植物治疗剂是锯叶棕(SR)。
本前瞻性研究设计了三个治疗组,分别为每日服用320毫克锯叶棕(N = 20)、每日服用0.4毫克坦索罗辛(TAM)(N = 20)以及锯叶棕 + 坦索罗辛组(N = 20),以揭示这些治疗方案在BPH治疗中的优越性或等效性。
在最大尿流率(Q(max))增加和国际前列腺症状评分(I-PSS)降低方面,各治疗组之间无统计学差异(P > 0.05)。锯叶棕治疗组未检测到不良反应。
锯叶棕和坦索罗辛单独治疗BPH似乎均有效。两者之间无一方优于另一方,此外,联合治疗(锯叶棕 + 坦索罗辛)并未带来额外益处。此外,锯叶棕耐受性良好,可作为治疗BPH所致下尿路症状(LUTS)的替代药物。